Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.
Approval Alert | Repotrectinib in NTRK Gene Fusion-Positive Solid Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
2
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
3
Why Is Burden of Care the Biggest Challenge of Cancer Treatment?
4
The Paradigm of AML Care: What’s New and What’s Changing
5
